Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer
- PMID: 21464397
- DOI: 10.1093/jnci/djr093
Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer
Abstract
Background: Ionizing radiation (IR) is effectively used in cancer therapy. However, in subsets of patients, a few radioresistant cancer cells survive and cause disease relapse with metastatic progression. The MET oncogene encodes the hepatocyte growth factor (HGF) receptor and is known to drive "invasive growth", a regenerative and prosurvival program unduly activated in metastasis.
Methods: Human tumor cell lines (MDA-MB-231, MDA-MB-435S, U251) were subjected to therapeutic doses of IR. MET mRNA, and protein expression and signal transduction were compared in treated and untreated cells, and the involvement of the DNA-damage sensor ataxia telangiectasia mutated (ATM) and the transcription factor nuclear factor kappa B (NF-κB) in activating MET transcription were analyzed by immunoblotting, chromatin immunoprecipitation, and use of NF-κB silencing RNA (siRNA). Cell invasiveness was measured in wound healing and transwell assays, and cell survival was measured in viability and clonogenic assays. MET was inhibited by siRNA or small-molecule kinase inhibitors (PHA665752 or JNJ-38877605). Combinations of MET-targeted therapy and radiotherapy were assessed in MDA-MB-231 and U251 xenografts (n = 5-6 mice per group). All P values were from two-sided tests.
Results: After irradiation, MET expression in cell lines was increased up to fivefold via activation of ATM and NF-κB. MET overexpression increased ligand-independent MET phosphorylation and signal transduction, and rendered cells more sensitive to HGF. Irradiated cells became more invasive via a MET-dependent mechanism that was further enhanced in the presence of HGF. MET silencing by siRNA or inhibition of its kinase activity by treatment with PHA665752 or JNJ-38877605 counteracted radiation-induced invasiveness, promoted apoptosis, and prevented cells from resuming proliferation after irradiation in vitro. Treatment with MET inhibitors enhanced the efficacy of IR to stop the growth of or to induce the regression of xenografts (eg, at day 13, U251 xenografts, mean volume increase relative to mean tumor volume at day 0: vehicle = 438%, 5 Gy IR = 151%, 5 Gy IR + JNJ-38877605 = 76%; difference, IR vs JNJ-38877604 + IR = 75%, 95% CI = 59% to 91%, P = .01).
Conclusion: IR induces overexpression and activity of the MET oncogene through the ATM-NF-κB signaling pathway; MET, in turn, promotes cell invasion and protects cells from apoptosis, thus supporting radioresistance. Drugs targeting MET increase tumor cell radiosensitivity and prevent radiation-induced invasiveness.
Comment in
-
How scatter factor receptor c-MET contributes to tumor radioresistance: ready, set, scatter!J Natl Cancer Inst. 2011 Apr 20;103(8):617-9. doi: 10.1093/jnci/djr103. Epub 2011 Apr 4. J Natl Cancer Inst. 2011. PMID: 21464396 No abstract available.
Similar articles
-
How scatter factor receptor c-MET contributes to tumor radioresistance: ready, set, scatter!J Natl Cancer Inst. 2011 Apr 20;103(8):617-9. doi: 10.1093/jnci/djr103. Epub 2011 Apr 4. J Natl Cancer Inst. 2011. PMID: 21464396 No abstract available.
-
Persistence of unrepaired DNA double strand breaks caused by inhibition of ATM does not lead to radio-sensitisation in the absence of NF-κB activation.DNA Repair (Amst). 2011 Feb 7;10(2):235-44. doi: 10.1016/j.dnarep.2010.11.005. Epub 2010 Dec 8. DNA Repair (Amst). 2011. PMID: 21144805
-
Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.Int J Oncol. 2004 Mar;24(3):591-608. Int J Oncol. 2004. PMID: 14767544
-
ATM-NF-kappaB connection as a target for tumor radiosensitization.Curr Cancer Drug Targets. 2007 Jun;7(4):335-42. doi: 10.2174/156800907780809769. Curr Cancer Drug Targets. 2007. PMID: 17979628 Free PMC article. Review.
-
The function, proteolytic processing, and histopathology of Met in cancer.Adv Cancer Res. 2009;103:1-23. doi: 10.1016/S0065-230X(09)03001-2. Adv Cancer Res. 2009. PMID: 19854350 Review.
Cited by
-
Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer.Cancers (Basel). 2022 Jul 15;14(14):3452. doi: 10.3390/cancers14143452. Cancers (Basel). 2022. PMID: 35884511 Free PMC article. Review.
-
The Prognostic Role of MET Protein Expression Among Surgically Resected Non-small Cell Lung Cancer Patients: A Meta-Analysis.Front Oncol. 2019 Dec 20;9:1441. doi: 10.3389/fonc.2019.01441. eCollection 2019. Front Oncol. 2019. PMID: 31921688 Free PMC article.
-
Simultaneous Inhibition of EGFR and HER2 via Afatinib Augments the Radiosensitivity of Nasopharyngeal Carcinoma Cells.J Cancer. 2019 May 12;10(9):2063-2073. doi: 10.7150/jca.29327. eCollection 2019. J Cancer. 2019. PMID: 31205567 Free PMC article.
-
Migration/Invasion of Malignant Gliomas and Implications for Therapeutic Treatment.Int J Mol Sci. 2018 Apr 8;19(4):1115. doi: 10.3390/ijms19041115. Int J Mol Sci. 2018. PMID: 29642503 Free PMC article. Review.
-
MET targeting: time for a rematch.Oncogene. 2020 Apr;39(14):2845-2862. doi: 10.1038/s41388-020-1193-8. Epub 2020 Feb 7. Oncogene. 2020. PMID: 32034310 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous